News|Articles|June 11, 2026

Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought mechanisms

Author(s)Ophthalmology Times Staff Reports

Three-year gene therapy data, an FDA reversal in wet AMD, light-powered dry eye treatment, a new macular supplement, and progress in childhood glaucoma—our review breaks down the 5 May 2026 stories that matter.

May 2026 was a busy stretch for clinical and translational eye care. The month brought multi-year durability data for 2 very different approaches to inherited retinal disease (IRD), a regulatory turnaround that could reshape the wet age-related macular degeneration (AMD) market, a genuinely novel mechanism for treating the ocular surface, and a new entry in the long-running conversation about macular nutrition. Here is what stood out.